Rigel Q2 net product sales $67M (+14% YoY); raises 2026 revenue guidance to $285-295M; in-licenses VEPPANU

RIGEL PHARMACEUTICALS INC

2026-Q2 EPS reported $1.32 revenue$137,521,000

Q2 2026 total revenues $78.7M, net income $17.3M ($0.88 diluted EPS); prior year net income $59.6M included $40M non-cash Lilly revenue.
TAVALISSE sales $47.4M (+18% YoY), REZLIDHIA $8.9M (+27%), GAVRETO $10.7M (-10%).
In-licensed VEPPANU (vepdegestrant) from Arvinas/Pfizer for $70M upfront; U.S. launch expected mid-August 2026.
2026 revenue guidance raised to $285-295M (ex-VEPPANU) from $275-290M; contract revenue guidance increased to ~$30M.
Cash & investments $95.3M at June 30, 2026, down from $155.0M at Dec 31, 2025 due to VEPPANU upfront payment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.